Schrödinger Inc. has announced a collaboration with Eli Lilly and Company to integrate Lilly's TuneLab™ platform into Schrödinger's LiveDesign enterprise informatics platform. This partnership aims to accelerate drug discovery and development by providing biotech companies with access to advanced artificial intelligence capabilities through LiveDesign. The integration will enable participating organizations to utilize TuneLab workflows while maintaining data privacy via federated learning. Both companies highlighted the collaboration as a step forward in leveraging digital and AI-driven drug design to benefit patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260109308931) on January 09, 2026, and is solely responsible for the information contained therein.